# SQ3370

Source: https://onco.cc/drugs/sq3370/  
OnCo record `sq3370` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SQ3370 is an experimental two-part treatment from Shasqi: a gel injected into a tumour, then an inactive form of the chemotherapy drug doxorubicin given into a vein, which the gel switches on. In its one trial, very high doses caused no dose-limiting side effects, but tumours responded no more often than with ordinary doxorubicin and the trial was stopped. It is not approved anywhere.

## Summary

SQ3370 is the first product of Shasqi's click-activated prodrug platform and, according to the company and the paper reporting it, the first use of click chemistry inside the human body in a clinical setting. It has two components that are given separately: SQL70, a tetrazine-modified hyaluronate biopolymer injected into one lesion, and SQP33, a trans-cyclooctene-modified doxorubicin prodrug infused daily. SQP33 was chosen in laboratory work from capped forms of four cytotoxic drugs.

Its only registered trial is NCT04106492, a phase 1/2a open-label study at ten centres in the United States and Australia that started in August 2020 and enrolled 53 people. Phase 1 (39 patients with advanced solid tumours) gave doxorubicin-equivalent doses from 0.38 to 15 times the standard dose per cycle with no dose-limiting toxicity reported and, in the authors' words, mild and manageable myelosuppression; 12 times the standard dose was chosen as the recommended phase 2 dose. Active doxorubicin was released rapidly at every dose level tested, and tumour and blood samples showed expansion and activation of cytotoxic CD8 T cells.

Phase 2a treated 14 patients with soft tissue sarcoma at the recommended dose. Two had an unconfirmed objective response (14.3 per cent) and ten had disease control (71.4 per cent, 95% CI 41.9 to 91.6). The authors state that the response rate was comparable to standard doxorubicin and that the study was terminated because the prespecified criterion for continuing, a response rate greater than that of standard doxorubicin, was not met. The registry gives the reason for stopping as the sponsor's decision, with primary completion on 7 September 2023.

No regulator has approved SQ3370 and no trial of it is open. Shasqi's pipeline, read on 16 November 2026, shows the biopolymer and doxorubicin programme for sarcoma as having reached the clinic and marks it "Partnering"; the company's June 2025 press release describes Shasqi as a preclinical company, and its newer programmes pair the same chemistry with tumour-binding proteins instead of an injected biopolymer.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-16
- Also known as: SQL70 plus SQP33; SQL70; SQP33; doxorubicin protodrug SQP33
- Tags: failure
- Code: SQ3370
- Modality: Click-activated anthracycline prodrug in two parts: an activating biopolymer injected into the tumour and an intravenous doxorubicin prodrug
- Mechanism: SQL70, a tetrazine-modified sodium hyaluronate biopolymer, is injected into a tumour. SQP33, doxorubicin capped with a trans-cyclooctene group that attenuates its activity, is then infused. Where SQP33 meets SQL70 the two react (a click reaction), the prodrug is captured at the tumour and native doxorubicin is released there.
- Payload: Doxorubicin, released from the prodrug SQP33
- Dosing: SQL70 by injection into a single tumour; SQP33 by intravenous infusion; In the trial: 10 or 20 mL of SQL70 on day 1 of each 21-day cycle, with SQP33 on days 1 to 5 (8 to 315 mg/m2 a day in dose escalation), or on days 1 to 3 in one phase 2a group. Recommended phase 2 dose posted on the registry: 1250 mg/m2 of SQP33 per cycle.

## Notes

- The clinical results are in a preprint (medRxiv, June 2025) that had not been peer reviewed when read; the dose-escalation part is also reported in Clinical Cancer Research (2025), and the registry posted results on 14 November 2025.
- The registry table counts 15 people in the phase 2a response analysis (two responses) because it includes one patient treated in a separate cohort below the recommended dose; the preprint counts 14.
- The company gives one standard dose as 75 mg/m2 of doxorubicin per cycle in molar equivalents (press release, 12 September 2022).
- No approval, designation or filing was found for SQ3370 in the sources read.

## Sources

- ClinicalTrials.gov NCT04106492, with posted results: https://clinicaltrials.gov/study/NCT04106492
- Chawla et al., medRxiv 2025 (phase 1/2a results, preprint): https://doi.org/10.1101/2025.06.02.25328445
- Srinivasan et al., Clinical Cancer Research 2025: https://doi.org/10.1158/1078-0432.CCR-24-2539
- Bui et al., ASCO 2024 abstract 11555 (phase 2a planned interim analysis): https://doi.org/10.1200/JCO.2024.42.16_suppl.11555
- Shasqi: platform page naming SQ3370: https://www.shasqi.com/our-platform
- Shasqi: pipeline (read 16 November 2026): https://www.shasqi.com/pipeline
- Shasqi press release: first patients dosed, 14 October 2020: https://www.shasqi.com/post/shasqi-announces-click-chemistry-breakthrough-with-first-ever-human-application-in-launch-of-clinical-program
- Shasqi press release: phase 2 opened, 12 September 2022: https://www.shasqi.com/post/shasqi-advances-sq3370-to-phase-2-in-solid-tumors

## Connected records

- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/)
- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Click-activated prodrugs (bioorthogonal drug activation in the body)](https://onco.cc/technologies/click-activated-prodrugs/)
- companies: [Shasqi](https://onco.cc/companies/shasqi/)
- terms: [Anthracyclines (doxorubicin, epirubicin)](https://onco.cc/terms/anthracycline/), [Dose-limiting toxicity (DLT)](https://onco.cc/terms/dose-limiting-toxicity/), [Prodrug](https://onco.cc/terms/prodrug/), [Recommended phase 2 dose (RP2D)](https://onco.cc/terms/rp2d/)
- trials: [SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a)](https://onco.cc/trials/nct04106492/)
- people: [Sant P. Chawla](https://onco.cc/people/sant-chawla/)
- key papers: [Click Activated Protodrugs Against Cancer: local capture and activation of capped chemotherapy by a tetrazine biopolymer](https://onco.cc/key-papers/paper-wu-click-activated-protodrugs-local-capture-chem-sci-2021/), [Local drug activation by bioorthogonal chemistry: an implanted hydrogel and a systemic doxorubicin prodrug in a sarcoma xenograft](https://onco.cc/key-papers/paper-mejia-oneto-local-hydrogel-systemic-prodrug-sarcoma-acs-cent-sci-2016/), [SQ3370 from preclinical evaluation to a first-in-human dose-escalation trial: the first click chemistry-based cancer therapeutic](https://onco.cc/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/), [SQ3370 in mice with two tumours: responses in the injected and the non-injected lesion](https://onco.cc/key-papers/paper-srinivasan-sq3370-injected-and-non-injected-lesions-adv-ther-2021/), [SQ3370 phase 1/2a results in advanced solid tumours and soft tissue sarcoma (preprint)](https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/)

---
JSON: https://onco.cc/api/v1/entities/sq3370.json